TFF Pharmaceuticals Inc
NASDAQ:TFFP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
TFF Pharmaceuticals Inc
EPS (Diluted)
TFF Pharmaceuticals Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
TFF Pharmaceuticals Inc
NASDAQ:TFFP
|
EPS (Diluted)
-$4
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
EPS (Diluted)
$8
|
CAGR 3-Years
21%
|
CAGR 5-Years
9%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
EPS (Diluted)
$3
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
14%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
EPS (Diluted)
$1
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
EPS (Diluted)
$7
|
CAGR 3-Years
8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
17%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
EPS (Diluted)
$22
|
CAGR 3-Years
49%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
TFF Pharmaceuticals Inc
Glance View
TFF Pharmaceuticals, Inc. engages in the development and commercialization of drug products based on its patented Thin Film Freezing technology platform. The company is headquartered in Austin, Texas. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform. Its TFF platform is designed to enable solubility of poorly water-soluble drugs. Its drug candidates include TFF Voriconazole Inhalation Powder (VIP), TFF Tacrolimus Inhalation Powder (TIP) and Triple Combination. The company is developing TFF VIP to treat invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease. TFF VIP is being developed as an inhaled dry powder drug. The company is developing TFF TIP, a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. The company is developing Triple Combination, a dry powder drug combination to treat chronic obstructive pulmonary disease (COPD) and asthma. Its other dry powder products include Inhaled SARS-CoV2 Monoclonal Antibody, Niclosamide Inhalation Powder, Cannabidiol (CBD) and Vaccines.
See Also
What is TFF Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
-4.2
USD
Based on the financial report for Sep 30, 2024, TFF Pharmaceuticals Inc's EPS (Diluted) amounts to -4.2 USD.
What is TFF Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-53%
Over the last year, the EPS (Diluted) growth was 66%. The average annual EPS (Diluted) growth rates for TFF Pharmaceuticals Inc have been -59% over the past three years , -53% over the past five years .
